Listen, we’ve got something important here, really important. We’re talking about the hearts of newborns, the little babies, and it’s a big deal in Türkiye. We did this huge study, the best study, from October 2021 to November 2022. We’re not playing around; we looked at 488 babies with critical heart issues in nine top-notch centers, entered all the data into this fancy Trials-Network system. It’s very high-tech, very impressive.

Now, the most common problem? It’s this thing called transposition of great arteria—it’s a big word, but basically, it’s a serious heart issue, and it’s affecting 19.5% of these kids. And get this, 12.9% of these little ones also have other health problems, not just the heart. It’s tough, really tough.

But we’re fighting back. We’ve got 325 of these kids into surgery—things like fixing the aortic arch, switching arteries around, and this Blalock-Taussig thing. It’s complicated, but we’re doing it. However, and this is sad, really sad, we’ve got an in-hospital mortality rate of 20.1%. That’s too high, way too high. And after surgery, we’re losing 19.6% of these kids. We’ve got to do better.

We’ve figured out the risks, too. If these babies need certain drugs before the surgery, if they’re really sick, if they have big complications after surgery, or if they need this machine called ECMO early on, their chances aren’t great. It’s tough, but we know what we’re up against.

So, what’s the bottom line? The mortality rate for these little fighters with critical heart issues is too high in our country. It’s not the same everywhere, but we’ve got to get those numbers down. We’re going to keep researching, keep working, because these babies, they deserve the best. And we’re going to give it to them, believe me.